Shield Therapeutics PLC (AIMTX, OTCQBHIEF) saw its share price rise 21% following a strong second-quarter trading update. The company reported that net revenues from its iron deficiency treatment, ACCRUFeR, doubled to $12.8 million, up from $6.4 million in Q1.
TX, OTCQB